NNMTi Powder

NNMTi Powder, or NNMT inhibitor, is a class of molecules that inhibit the enzyme's activity. It is the abbreviation of Nicotinamide N-methyltransferase inhibitors, a class of drugs or supplements that target the NNMT enzyme. NNMT plays an important role in the aging process of various metabolic diseases. By regulating NAD⁺ metabolism and methylation status, NNMT inhibitors are expected to bring new strategies for treating metabolic disorders, muscle decline, chronic diseases, and pathological changes.

Shaanxi Medibridge Biotech Co., Ltd. focuses on the supply of pharmaceutical raw materials and research-use compounds. We support customers with stable quality, clear specification communication, flexible packaging options, and document-related support for different project stages.

5-Amino-1-methylquinolin-1-ium iodide can be used to treat age-related defects in muscle stem cell activity, thereby promoting superior regeneration following injury to aging muscle. It is a potent inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT is a methyltransferase that methylates nicotinamide (NAM) in vivo to produce N1-methylnicotinamide (MNAM) for excretion. Recent studies indicate that, beyond clearing NAM, NNMT regulates various metabolic pathways in tissues such as adipose and liver by consuming methyl donors and generating active metabolites.

Nicotinamide N-methyltransferase (NNMT) is a key cytosolic biotransformation enzyme responsible for catalyzing the N-methylation of endogenous and exogenous xenobiotics. Researchers screened a series of small-molecule NNMT inhibitors spanning three orders of magnitude in activity and systematically established their structure-activity relationships (SAR). Screening of N-methylated quinolinium and 5-amino-1-methylquinolin-1-ium iodide analogs revealed that the quinolinium compound 5-amino-1-methylquinolin-1-ium iodide possesses significant inhibitory activity, demonstrating potential as a lead structure. Computational docking of 5-amino-1-methylquinolin-1-ium iodide into the NNMT substrate (nicotinamide) binding site revealed a significant correlation between the docking scores of ligand-enzyme interactions and experimentally determined IC50 values. Predictive analysis of the binding conformations of quinolinium analogs elucidated their selective binding patterns with residues in the NNMT substrate-binding site, as well as the key chemical features driving protein-ligand interactions and NNMT inhibition.

NNMT inhibition may reduce the amount of nicotinamide (NAM) converted to 1-methylnicotinamide (1-MNA) and alter the consumption of the methyl donor S-adenosylmethionine (SAM). This does not mean that inhibiting NNMT will necessarily raise NAD⁺ throughout the body. NAM must still pass through other enzymes in the NAD⁺ salvage pathway, and the response can vary by tissue and metabolic state.

A mouse study published in 2014 found that Nnmt knockdown in adipose tissue and liver was associated with changes in adipose SAM, NAD⁺, energy expenditure, histone methylation, and polyamine metabolism. These findings support NNMT as a metabolic research target, but the effects of genetic knockdown cannot be assumed to match those of every NNMT inhibitor powder.

5-Amino-1MQ has been investigated in cultured adipocytes and diet-induced obese mice. Researchers measured endpoints including intracellular 1-MNA, lipid formation, body weight, adipose tissue mass, and adipocyte size. Another NNMT inhibitor, JBSNF-000088, produced findings related to insulin sensitivity and glucose regulation in animal models of metabolic disease.

Results in obese mice do not establish weight-loss efficacy in humans. In some follow-up experiments, inhibitor treatment was combined with a dietary change, so the effects of the compound, diet, and their interaction must be distinguished.

NNMT research extends beyond adipose tissue. A 2025 study examined NNMT in cancer-associated fibroblasts (CAFs) using spatial transcriptomics, single-cell analysis, genetic knockout, and pharmacological inhibition. The investigators explored how NNMT activity may shape an immunosuppressive tumor microenvironment. A specific inhibitor developed in that study produced effects in several mouse tumor models.

The distinction is between NNMT as a promising research target and a particular powder having demonstrated anticancer activity. The study tested a specifically identified and validated inhibitor. Its findings cannot automatically be applied to 5-amino-1MQ or to a product labeled only "NNMTi Powder."

"NNMTi" describes a class of compounds, so it cannot be assigned a single safety profile. Individual inhibitors may differ substantially in chemical structure, selectivity, tissue distribution, metabolism, and exposure. Research on a specific compound should assess:

- Off-target effects on other methyltransferases and related metabolic enzymes;

- Liver, kidney, and other tissue exposure and toxicity;

- The consequences of prolonged changes in NAM, 1-MNA, NAD⁺, and methyl-donor balance;

- Dose–response relationships under the intended route of administration and formulation;

- Reproductive, developmental, and long-term safety where relevant.

The frequently cited metabolic studies of 5-amino-1MQ remain centered on cell and animal proof-of-concept experiments.